Natural killer cell infusion after remission for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding natural killer (NK) cell infusions to standard consolidation chemotherapy helps keep acute myeloid leukemia (AML) in remission. It's for people with AML who are already in remission after their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 59 years old, or between 60 and 75 if you are generally healthy.
- You have been diagnosed with acute myeloid leukemia (AML), but not a subtype called acute promyelocytic leukemia (APL).
- You are in your first complete remission after initial treatment.
- You are healthy enough to receive a type of chemotherapy called high-dose cytarabine.
- You have not had serious heart problems (like heart failure or a heart attack) in the last 6 months.
- You have a donor who shares half of your immune system markers (a haploidentical donor), usually a family member.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving special immune cells from a donor can clear leftover leukemia cells in patients who are in remission but still have traces of cancer after chemotherapy.
This trial tests a new treatment using immune cells (called natural killer cells) derived from stem cells to help fight AML that has returned or not responded to standard therapy. The goal is to see if these cells can safely and effectively control the leukemia.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a treatment using natural killer (NK) cells combined with antibodies to fight a type of blood cancer called acute myeloid leukemia (AML). It is for people whose AML has come back or not improved with standard treatments.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
Hear when a new Acute Myeloid Leukaemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.